ApcinteX

ApcinteX is a Cambridge, England-based biopharmaceutical company developing novel anticoagulant treatments for bleeding disorders such as hemophilia by targeting the protein C natural anticoagulant pathway. The firm's lead therapeutic candidate, SerpinPC, is designed to inhibit the activated protein C pathway to restore normal blood clotting capacity, providing an alternative to traditional factor replacement therapy. Prior to its acquisition, the enterprise raised £14 million in a 2019 Series A funding round led by Medicxi to advance its Phase 2a clinical studies. In February 2021, ApcinteX was acquired and integrated into Centessa Pharmaceuticals, a consolidated entity of 10 private biotech companies launched with $250 million in Series A financing backed by investors including General Atlantic and Vida Ventures. The University of Cambridge spin-out was originally founded in 2014 by Trevor Baglin, Jim Huntington, and David Grainger.